Marinus Pharma (MRNS) Misses Q2 EPS by 4c ; Offers Guidance

Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.63), $0.04 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $8.06 million versus the consensus estimate of $9.5 million.

GUIDANCE:

Marinus Pharma sees FY2024 revenue of $33-35 million, versus the consensus of $39.35 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Jefferies Downgrades Fluence Energy Inc. (FLNC) to Hold
• BofA Securities Reiterates Buy Rating on Tradeweb Markets (TW) Post Management Meet
• Moncler SpA (MONC:IM) (MONRY) PT Lowered to EUR50 at Morgan Stanley